US-Listed In Vitro & In Vivo Diagnostic Substances — Total Assets Percentiles, FY 2022

Population: 21 US-listed companies (SIC 2835), fiscal year 2022; fiscal year ends 2022-06-30 to 2023-05-31.

Fiscal year: 2019 · 2020 · 2021 · 2022 · 2023 · 2024 · 2025 · latest

10th percentile	$4.4M
25th percentile	$17.4M
Median	$100.1M
75th percentile	$1.2B
90th percentile	$2.7B
Mean	$1.0B
Minimum	$1.9k
Maximum	$8.9B

Methodology & sources
Total Assets as filed, one fiscal year per company; percentiles computed in the database via percentile_cont, never by a model. Fiscal year 2022 = fiscal years ending 2022-06-01 to 2023-05-31 (majority-overlap rule; June-ending fiscal years count toward the ending calendar year).
Source: SEC EDGAR filings (public domain). Data: FACTANKER registry, precomputed 2026-09-03.

Evidence samples

Latest Total Assets percentiles (live) · All In Vitro & In Vivo Diagnostic Substances benchmarks · All industries

Cite as: FACTANKER, https://factanker.com/industries/sic-2835/total-assets/2022